Patents Assigned to Bessor Pharma, LLC
  • Patent number: 11685724
    Abstract: The present invention relates to intermediate compounds for the synthesis of novel cannabinoids 1 and 2, synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization and, for tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2 are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol. The analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis oil. Novel compounds of the formulas 3 and 6, useful as intermediates for the synthesis of the cannabinoids of advanced intermediates 4 and 5 as well as cannabinoids of the formulas 1 and 2, are disclosed.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: June 27, 2023
    Assignee: Bessor Pharma, LLC
    Inventors: Barry A. Berkowitz, Anthony G. Barrett, Daniel Elliott
  • Patent number: 11407724
    Abstract: A process for the preparation of substantially pure diverse known and novel cannabinoids 1 and 2, which include ?9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), cannabidiol (11), cannabidivarin (12) and other naturally occurring tetracyclic and tricyclic cannabinoids and other synthetic tetracyclic and tricyclic analogues, via intermediates 3, 6, 4 and 5, using a cascade sequence of allylic rearrangement, aromatization and, for the tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2, including ?9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: August 9, 2022
    Assignee: Bessor Pharma, LLC
    Inventors: Barry A. Berkowitz, Anthony G. Barrett, Daniel Elliott
  • Patent number: 11370768
    Abstract: The present invention relates to novel cannabinoids 1 and 2, synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization and, for tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2 are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol. The analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis oil. Novel compounds of the formulas 3, 4, 5 and 6, as intermediates for the synthesis of the cannabinoids of the formulas 1 and 2 are also disclosed.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: June 28, 2022
    Assignee: Bessor Pharma, LLC
    Inventors: Barry A. Berkowitz, Anthony G. Barrett, Daniel Elliott